CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) insider Linda C. Hogan sold 2,581 shares of the stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $37.22, for a total value of $96,064.82. Following the transaction, the insider now owns 719 shares in the company, valued at approximately $26,761.18. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) opened at 36.91 on Tuesday. CoLucid Pharmaceuticals Inc. has a 12-month low of $3.60 and a 12-month high of $39.27. The firm’s market capitalization is $565.98 million. The stock’s 50 day moving average price is $24.44 and its 200 day moving average price is $11.74.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.22. Equities research analysts expect that CoLucid Pharmaceuticals Inc. will post ($3.91) earnings per share for the current year.
CLCD has been the topic of several recent research reports. Ladenburg Thalmann set a $57.00 price objective on CoLucid Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 19th. Stifel Nicolaus increased their target price on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, September 19th. Piper Jaffray Cos. reissued a “buy” rating and set a $36.00 target price on shares of CoLucid Pharmaceuticals in a report on Thursday, September 15th. Finally, Zacks Investment Research raised CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $33.05.
Several hedge funds have recently modified their holdings of CLCD. Societe Generale purchased a new stake in shares of CoLucid Pharmaceuticals during the second quarter valued at about $464,000. FMR LLC purchased a new stake in shares of CoLucid Pharmaceuticals during the second quarter valued at about $554,000. Finally, Vanguard Group Inc. raised its stake in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 30.47% of the company’s stock.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.